Which has better valuation & earnings, HNGE or NEO?

NeoGenomics has higher revenue and earnings than Hinge Health. NeoGenomics is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hinge Health $587.86M 14.11 -$528.26M $1.28 80.33 NeoGenomics $727.33M 2.89 -$108.03M -$0.40 N/A

Is HNGE or NEO more profitable?

Hinge Health has a net margin of 15.15% compared to NeoGenomics' net margin of -6.77%. Hinge Health's return on equity of 51.60% beat NeoGenomics' return on equity. Company Net Margins Return on Equity Return on Assets Hinge Health 15.15% 51.60% 14.16% NeoGenomics -6.77% -1.99% -1.21%

Does the media favor HNGE or NEO?

In the previous week, NeoGenomics had 12 more articles in the media than Hinge Health. MarketBeat recorded 23 mentions for NeoGenomics and 11 mentions for Hinge Health. Hinge Health's average media sentiment score of 0.44 beat NeoGenomics' score of 0.25 indicating that Hinge Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hinge Health 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NeoGenomics 2 Very Positive mention(s) 3 Positive mention(s) 14 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer NEO or HIMS?

In the previous week, Hims & Hers Health had 9 more articles in the media than NeoGenomics. MarketBeat recorded 32 mentions for Hims & Hers Health and 23 mentions for NeoGenomics. NeoGenomics' average media sentiment score of 0.25 beat Hims & Hers Health's score of 0.12 indicating that NeoGenomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeoGenomics 2 Very Positive mention(s) 3 Positive mention(s) 14 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hims & Hers Health 5 Very Positive mention(s) 4 Positive mention(s) 23 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, CHE or NEO?

Chemed has higher revenue and earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemed $2.53B 2.58 $265.24M $19.91 25.07 NeoGenomics $727.33M 2.89 -$108.03M -$0.40 N/A

Is CHE or NEO more profitable?

Chemed has a net margin of 10.60% compared to NeoGenomics' net margin of -6.77%. Chemed's return on equity of 31.77% beat NeoGenomics' return on equity. Company Net Margins Return on Equity Return on Assets Chemed 10.60% 31.77% 18.90% NeoGenomics -6.77% -1.99% -1.21%

Does the media favor CHE or NEO?

In the previous week, NeoGenomics had 17 more articles in the media than Chemed. MarketBeat recorded 23 mentions for NeoGenomics and 6 mentions for Chemed. NeoGenomics' average media sentiment score of 0.25 beat Chemed's score of 0.15 indicating that NeoGenomics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chemed 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NeoGenomics 2 Very Positive mention(s) 3 Positive mention(s) 14 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to BLLN or NEO?

In the previous week, NeoGenomics had 10 more articles in the media than Billiontoone. MarketBeat recorded 23 mentions for NeoGenomics and 13 mentions for Billiontoone. NeoGenomics' average media sentiment score of 0.25 beat Billiontoone's score of 0.11 indicating that NeoGenomics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Billiontoone 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral NeoGenomics 2 Very Positive mention(s) 3 Positive mention(s) 14 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, NEO or RDNT?

RadNet has higher revenue and earnings than NeoGenomics. RadNet is trading at a lower price-to-earnings ratio than NeoGenomics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeoGenomics $727.33M 2.89 -$108.03M -$0.40 N/A RadNet $2.27B 2.46 -$18.65M -$0.27 N/A

Is NEO or RDNT more profitable?

RadNet has a net margin of -0.93% compared to NeoGenomics' net margin of -6.77%. RadNet's return on equity of 2.61% beat NeoGenomics' return on equity. Company Net Margins Return on Equity Return on Assets NeoGenomics -6.77% -1.99% -1.21% RadNet -0.93% 2.61% 0.91%

Does the media prefer NEO or RDNT?

In the previous week, NeoGenomics had 20 more articles in the media than RadNet. MarketBeat recorded 23 mentions for NeoGenomics and 3 mentions for RadNet. RadNet's average media sentiment score of 0.58 beat NeoGenomics' score of 0.25 indicating that RadNet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeoGenomics 2 Very Positive mention(s) 3 Positive mention(s) 14 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral RadNet 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

NeoGenomics (NEO) Competitors

$16.35 +0.33 (+2.06%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$16.26 -0.10 (-0.58%)

As of 10/9/2026 07:30 PM Eastern

Compare

NEO vs. HNGE, HIMS, CHE, BLLN, and RDNT

Should you buy NeoGenomics stock or one of its competitors? NeoGenomics's main competitors and comparable companies include Hinge Health (HNGE), Hims & Hers Health (HIMS), Chemed (CHE), Billiontoone (BLLN), and RadNet (RDNT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does NeoGenomics compare to Hinge Health?

Hinge Health (NYSE:HNGE) and NeoGenomics (NASDAQ:NEO) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

In the previous week, NeoGenomics had 12 more articles in the media than Hinge Health. MarketBeat recorded 23 mentions for NeoGenomics and 11 mentions for Hinge Health. Hinge Health's average media sentiment score of 0.44 beat NeoGenomics' score of 0.25 indicating that Hinge Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hinge Health	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeoGenomics	2 Very Positive mention(s)	3 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NeoGenomics has higher revenue and earnings than Hinge Health. NeoGenomics is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hinge Health	$587.86M	14.11	-$528.26M	$1.28	80.33
NeoGenomics	$727.33M	2.89	-$108.03M	-$0.40	N/A

Hinge Health has a net margin of 15.15% compared to NeoGenomics' net margin of -6.77%. Hinge Health's return on equity of 51.60% beat NeoGenomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hinge Health	15.15%	51.60%	14.16%
NeoGenomics	-6.77%	-1.99%	-1.21%

Hinge Health currently has a consensus price target of $105.33, indicating a potential upside of 2.44%. NeoGenomics has a consensus price target of $18.17, indicating a potential upside of 11.11%. Given NeoGenomics' higher possible upside, analysts clearly believe NeoGenomics is more favorable than Hinge Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hinge Health	0 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.89
NeoGenomics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Hinge Health has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market. Comparatively, NeoGenomics has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market.

98.5% of NeoGenomics shares are owned by institutional investors. 18.9% of Hinge Health shares are owned by insiders. Comparatively, 1.1% of NeoGenomics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Hinge Health beats NeoGenomics on 11 of the 17 factors compared between the two stocks.

How does NeoGenomics compare to Hims & Hers Health?

NeoGenomics (NASDAQ:NEO) and Hims & Hers Health (NYSE:HIMS) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

Hims & Hers Health has higher revenue and earnings than NeoGenomics. Hims & Hers Health is trading at a lower price-to-earnings ratio than NeoGenomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeoGenomics	$727.33M	2.89	-$108.03M	-$0.40	N/A
Hims & Hers Health	$2.35B	3.07	$128.37M	-$0.63	N/A

Hims & Hers Health has a net margin of -5.51% compared to NeoGenomics' net margin of -6.77%. NeoGenomics' return on equity of -1.99% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeoGenomics	-6.77%	-1.99%	-1.21%
Hims & Hers Health	-5.51%	-6.51%	-1.20%

98.5% of NeoGenomics shares are held by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are held by institutional investors. 1.1% of NeoGenomics shares are held by company insiders. Comparatively, 11.8% of Hims & Hers Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

NeoGenomics has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.44, meaning that its share price is 144% more volatile than the broader market.

In the previous week, Hims & Hers Health had 9 more articles in the media than NeoGenomics. MarketBeat recorded 32 mentions for Hims & Hers Health and 23 mentions for NeoGenomics. NeoGenomics' average media sentiment score of 0.25 beat Hims & Hers Health's score of 0.12 indicating that NeoGenomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeoGenomics	2 Very Positive mention(s)	3 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hims & Hers Health	5 Very Positive mention(s)	4 Positive mention(s)	23 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NeoGenomics currently has a consensus price target of $18.17, suggesting a potential upside of 11.11%. Hims & Hers Health has a consensus price target of $32.43, suggesting a potential upside of 5.08%. Given NeoGenomics' stronger consensus rating and higher probable upside, equities analysts clearly believe NeoGenomics is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeoGenomics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Hims & Hers Health	1 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

Summary

NeoGenomics and Hims & Hers Health tied by winning 8 of the 16 factors compared between the two stocks.

How does NeoGenomics compare to Chemed?

Chemed (NYSE:CHE) and NeoGenomics (NASDAQ:NEO) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

In the previous week, NeoGenomics had 17 more articles in the media than Chemed. MarketBeat recorded 23 mentions for NeoGenomics and 6 mentions for Chemed. NeoGenomics' average media sentiment score of 0.25 beat Chemed's score of 0.15 indicating that NeoGenomics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemed	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeoGenomics	2 Very Positive mention(s)	3 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Chemed presently has a consensus price target of $554.60, suggesting a potential upside of 11.11%. NeoGenomics has a consensus price target of $18.17, suggesting a potential upside of 11.11%. Given Chemed's higher possible upside, research analysts plainly believe Chemed is more favorable than NeoGenomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemed	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29
NeoGenomics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Chemed has a net margin of 10.60% compared to NeoGenomics' net margin of -6.77%. Chemed's return on equity of 31.77% beat NeoGenomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemed	10.60%	31.77%	18.90%
NeoGenomics	-6.77%	-1.99%	-1.21%

95.9% of Chemed shares are owned by institutional investors. Comparatively, 98.5% of NeoGenomics shares are owned by institutional investors. 3.3% of Chemed shares are owned by insiders. Comparatively, 1.1% of NeoGenomics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Chemed has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, NeoGenomics has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market.

Chemed has higher revenue and earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemed	$2.53B	2.58	$265.24M	$19.91	25.07
NeoGenomics	$727.33M	2.89	-$108.03M	-$0.40	N/A

Summary

Chemed beats NeoGenomics on 9 of the 16 factors compared between the two stocks.

How does NeoGenomics compare to Billiontoone?

Billiontoone (NASDAQ:BLLN) and NeoGenomics (NASDAQ:NEO) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Billiontoone currently has a consensus target price of $126.25, suggesting a potential upside of 28.71%. NeoGenomics has a consensus target price of $18.17, suggesting a potential upside of 11.11%. Given Billiontoone's stronger consensus rating and higher probable upside, equities research analysts plainly believe Billiontoone is more favorable than NeoGenomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Billiontoone	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55
NeoGenomics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Billiontoone has a net margin of 8.04% compared to NeoGenomics' net margin of -6.77%. Billiontoone's return on equity of 9.96% beat NeoGenomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Billiontoone	8.04%	9.96%	5.35%
NeoGenomics	-6.77%	-1.99%	-1.21%

98.5% of NeoGenomics shares are held by institutional investors. 50.2% of Billiontoone shares are held by company insiders. Comparatively, 1.1% of NeoGenomics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Billiontoone has higher earnings, but lower revenue than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Billiontoone	$305.11M	15.17	$7.45M	$0.70	140.13
NeoGenomics	$727.33M	2.89	-$108.03M	-$0.40	N/A

In the previous week, NeoGenomics had 10 more articles in the media than Billiontoone. MarketBeat recorded 23 mentions for NeoGenomics and 13 mentions for Billiontoone. NeoGenomics' average media sentiment score of 0.25 beat Billiontoone's score of 0.11 indicating that NeoGenomics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Billiontoone	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
NeoGenomics	2 Very Positive mention(s)	3 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Billiontoone beats NeoGenomics on 11 of the 15 factors compared between the two stocks.

How does NeoGenomics compare to RadNet?

NeoGenomics (NASDAQ:NEO) and RadNet (NASDAQ:RDNT) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

In the previous week, NeoGenomics had 20 more articles in the media than RadNet. MarketBeat recorded 23 mentions for NeoGenomics and 3 mentions for RadNet. RadNet's average media sentiment score of 0.58 beat NeoGenomics' score of 0.25 indicating that RadNet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeoGenomics	2 Very Positive mention(s)	3 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
RadNet	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NeoGenomics has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market. Comparatively, RadNet has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market.

RadNet has higher revenue and earnings than NeoGenomics. RadNet is trading at a lower price-to-earnings ratio than NeoGenomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeoGenomics	$727.33M	2.89	-$108.03M	-$0.40	N/A
RadNet	$2.27B	2.46	-$18.65M	-$0.27	N/A

98.5% of NeoGenomics shares are held by institutional investors. Comparatively, 77.9% of RadNet shares are held by institutional investors. 1.1% of NeoGenomics shares are held by insiders. Comparatively, 5.1% of RadNet shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

RadNet has a net margin of -0.93% compared to NeoGenomics' net margin of -6.77%. RadNet's return on equity of 2.61% beat NeoGenomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeoGenomics	-6.77%	-1.99%	-1.21%
RadNet	-0.93%	2.61%	0.91%

NeoGenomics currently has a consensus price target of $18.17, suggesting a potential upside of 11.11%. RadNet has a consensus price target of $90.00, suggesting a potential upside of 26.92%. Given RadNet's stronger consensus rating and higher probable upside, analysts plainly believe RadNet is more favorable than NeoGenomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeoGenomics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
RadNet	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Summary

RadNet beats NeoGenomics on 11 of the 17 factors compared between the two stocks.

Get NeoGenomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NEO vs. The Competition

Export

Metric	NeoGenomics	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.06B	$9.81B	$7.16B	$13.21B
Dividend Yield	N/A	2.61%	2.53%	16.37%
P/E Ratio	-40.88	34.10	275.30	26.16
Price / Sales	2.74	4.87	635.97	107.53
Price / Cash	47.81	115.75	76.38	53.09
Price / Book	2.53	5.11	11.22	6.33
Net Income	-$108.03M	$315.68M	$3.50B	$382.15M
7 Day Performance	-11.48%	-0.38%	-0.89%	-1.40%
1 Month Performance	-7.16%	-1.97%	-4.42%	-3.47%
1 Year Performance	79.67%	12.76%	7.03%	1.18%

NeoGenomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NEO NeoGenomics	2.3901 of 5 stars	$16.35 +2.1%	$18.17 +11.1%	+82.3%	$2.06B	$766.30M	N/A	2,500	Analyst Forecast
HNGE Hinge Health	2.4607 of 5 stars	$92.26 -3.5%	$103.71 +12.4%	+103.8%	$7.71B	$587.86M	72.08	1,437	Analyst Downgrade Insider Trade
HIMS Hims & Hers Health	1.6645 of 5 stars	$28.72 -2.4%	$32.43 +12.9%	-46.9%	$6.86B	$2.35B	N/A	2,442	Trending News
CHE Chemed	4.4369 of 5 stars	$513.56 +0.3%	$554.60 +8.0%	+15.8%	$6.69B	$2.53B	25.79	15,811	News Coverage Analyst Upgrade
BLLN Billiontoone	4.1387 of 5 stars	$121.72 -1.1%	$125.88 +3.4%	N/A	$5.81B	$305.11M	173.89	713	Analyst Downgrade Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NEO) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeoGenomics (NEO) Competitors

NEO vs. HNGE, HIMS, CHE, BLLN, and RDNT

How does NeoGenomics compare to Hinge Health?

Summary

How does NeoGenomics compare to Hims & Hers Health?

Summary

How does NeoGenomics compare to Chemed?

Summary

How does NeoGenomics compare to Billiontoone?

Summary

How does NeoGenomics compare to RadNet?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEO vs. The Competition

NeoGenomics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeoGenomics (NEO) Competitors

NEO vs. HNGE, HIMS, CHE, BLLN, and RDNT

How does NeoGenomics compare to Hinge Health?

Does the media favor HNGE or NEO?

Which has better valuation & earnings, HNGE or NEO?

Is HNGE or NEO more profitable?

Do analysts rate HNGE or NEO?

Which has more volatility and risk, HNGE or NEO?

Do institutionals & insiders have more ownership in HNGE or NEO?

Summary

How does NeoGenomics compare to Hims & Hers Health?

Which has higher valuation & earnings, NEO or HIMS?

Is NEO or HIMS more profitable?

Do institutionals & insiders have more ownership in NEO or HIMS?

Which has more volatility and risk, NEO or HIMS?

Does the media prefer NEO or HIMS?

Do analysts recommend NEO or HIMS?

Summary

How does NeoGenomics compare to Chemed?

Does the media favor CHE or NEO?

Do analysts prefer CHE or NEO?

Is CHE or NEO more profitable?

Do institutionals and insiders have more ownership in CHE or NEO?

Which has more volatility and risk, CHE or NEO?

Which has better valuation & earnings, CHE or NEO?

Summary

How does NeoGenomics compare to Billiontoone?

Do analysts recommend BLLN or NEO?

Is BLLN or NEO more profitable?

Do institutionals & insiders have more ownership in BLLN or NEO?

Which has preferable earnings & valuation, BLLN or NEO?

Does the media refer more to BLLN or NEO?

Summary

How does NeoGenomics compare to RadNet?

Does the media prefer NEO or RDNT?

Which has more volatility & risk, NEO or RDNT?

Which has better earnings & valuation, NEO or RDNT?

Do insiders & institutionals believe in NEO or RDNT?

Is NEO or RDNT more profitable?

Do analysts recommend NEO or RDNT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEO vs. The Competition

NeoGenomics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools